Welcome to our dedicated page for Masimo SEC filings (Ticker: MASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Masimo Corporation (MASI) SEC filings page on Stock Titan provides access to the company e2 80 99s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Masimo, a Delaware corporation and global medical technology company, reports under Commission File Number 001-33642. Its filings offer detailed insight into financial performance, corporate actions, and material events related to its healthcare-focused monitoring technologies and related operations.
Recent Form 8-K filings document key developments, such as quarterly financial results, guidance updates, and significant transactions. For example, Masimo filed a Form 8-K on November 4, 2025, furnishing a press release that reported third quarter 2025 financial results for its continuing healthcare operations and provided updated full-year 2025 guidance. Earlier, on August 5, 2025, the company filed a Form 8-K to furnish second quarter 2025 results and supplemental financial information.
Masimo e2 80 99s filings also record corporate events beyond earnings. A Form 8-K dated September 23, 2025 describes the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, including the transfer of Masimo e2 80 99s equity interests in Viper Holdings Corporation and related cash consideration. Another Form 8-K filed on August 19, 2025 notes the resignation of a board member, while additional 8-Ks provide unaudited pro forma financial information following the Sound United transaction.
Within these filings, Masimo explains its use of non-GAAP financial measures, outlining adjustments for items such as acquisition-related amortization, business transition and related costs, litigation-related expenses and settlements, realized and unrealized gains or losses, financing-related adjustments, and tax impacts. Investors reviewing this page can use the underlying documents alongside Stock Titan e2 80 99s AI-powered summaries to understand Masimo e2 80 99s reported GAAP and non-GAAP results, the impact of significant transactions, and disclosures about ongoing Apple-related litigation expenses. The filings archive is a primary source for Masimo e2 80 99s official, time-stamped communications with regulators and the market.
Danaher Corporation plans to acquire Masimo Corporation in an all-cash deal valuing Masimo at $180 per share, or about $9.9 billion in enterprise value including assumed debt and net of cash. Masimo is a leading provider of pulse oximetry and other patient monitoring technologies, mainly for acute care.
Masimo will operate as a standalone business within Danaher’s Diagnostics segment alongside brands such as Radiometer and Beckman Coulter Diagnostics. Danaher expects Masimo to deliver high-single digit core revenue growth over the long term and to generate more than $530 million of EBITDA in 2027.
The acquisition is projected to increase Danaher’s adjusted diluted net earnings per share by $0.15–$0.20 in the first full year and about $0.70 in the fifth full year. Danaher also targets over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year. Closing is anticipated in the second half of 2026, subject to regulatory clearances and Masimo shareholder approval, and will be funded with cash on hand and new debt.
Masimo Corporation agreed to be acquired by Danaher Corporation in an all-cash merger valuing Masimo at $180.00 per share, or about $9.9 billion. Masimo will become a standalone business unit within Danaher’s Diagnostics segment and continue operating under the Masimo brand.
The deal requires approval from Masimo stockholders, antitrust and foreign investment clearances, and other customary closing conditions. A voting agreement with Politan Capital Management supports the merger, and Masimo could owe Danaher a $305 million termination fee in certain scenarios. Closing is expected in the second half of 2026, after which Masimo’s shares will be delisted and deregistered.
Masimo Corporation: Joe Kiani reports beneficial ownership of 5,904,629 shares of common stock, representing 10.3% of the class as calculated in the filing. The reported total combines issued shares and multiple equity awards that the filer says remain issuable but which the company has not issued.
The filing details that 368,252 shares relate to exercised options the company declined to process and that the filer includes 2,700,000 RSUs, 158,450 accelerated options, 198,225 PSUs, and 85,255 vested options among the components of the aggregate beneficial ownership; several of those items are subject to a dispute described in footnotes.
Masimo Corporation CEO Catherine M. Szyman reported equity compensation activity on February 12, 2026. She exercised 11,141 restricted stock units (RSUs), converting them into 11,141 shares of common stock at a price of $132.96 per share. Of these, 4,568 shares were withheld by Masimo to cover tax withholding obligations tied to the vesting of performance RSUs, leaving her with 6,573 shares of common stock held directly. Following the transaction, she also directly held 22,283 RSUs, which continue to represent the right to receive an equal number of common shares upon future vesting.
Masimo Corporation executive Sampath Anand, EVP of Ops & Clinical Research, exercised stock options and sold shares of common stock. On January 28, 2026, he exercised 30,000 non-qualified stock options at an exercise price of $37.84 per share, receiving 30,000 shares.
That same day he sold Masimo common stock in three transactions under a Rule 10b5-1 sales plan dated September 12, 2025. He sold 11,924 shares at a weighted average price of $136.56, 6,560 shares at $137.22, and 196 shares at $138.09. Following these transactions, he directly owned 40,909 Masimo shares.
Masimo Corporation has received a notice under Rule 144 for the proposed sale of 18,680 shares of its common stock through broker Charles Schwab & Co., Inc. on NASDAQ. The aggregate market value of the shares listed for sale is $2,555,567.00.
The seller acquired the 18,680 shares on 01/28/2026 through an employee stock option exercise, with a broker-facilitated cashless exercise used as payment. The filing notes that 53,713,949 common shares are outstanding and includes standard representations about the absence of undisclosed material adverse information.
BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting its beneficial ownership of MASIMO CORPORATION common stock as of 12/31/2025. The firm reports beneficial ownership of 4,386,302 shares of common stock, representing 8.2% of the outstanding class. It has sole power to vote 4,290,570 shares and sole power to dispose of 4,386,302 shares, with no shared voting or dispositive power.
The filing explains that the shares are held by certain business units of BlackRock, Inc. and affiliates, and that various underlying persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares. BlackRock Portfolio Management LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Masimo.
Masimo Corporation filed an 8-K describing how it is sharing early views of its recent performance. On January 12, 2026, the company issued a press release with select preliminary financial results for the fourth quarter and full year ended January 3, 2026, with full audited figures to follow.
Management plans to review complete fourth quarter and full-year 2025 results after the market closes on February 26, 2026. On the same day as the filing, the CEO and EVP & CFO discussed select preliminary results at the 44th Annual J.P. Morgan Healthcare Conference, and Masimo also made available a supplemental 2025 earnings presentation and non-GAAP information as furnished exhibits.
Masimo Corporation (MASI) reported an insider equity transaction by its CTIO and EVP of Engineering on November 13, 2025. A previously granted award of 2,474 restricted stock units (RSUs), originally granted on November 13, 2024, vested in full and was converted into the same number of shares of common stock. To cover tax withholding obligations tied to this vesting, 974 shares were withheld by the company at a stated price of $152.43 per share for the acquisition transaction and $0 for the tax withholding entry. Following these transactions, the officer directly held 3,268 shares of Masimo common stock, reflecting the updated beneficial ownership after the RSU vesting and tax withholding.
Masimo Corporation reported third‑quarter results reflecting solid performance in healthcare operations and the completion of its consumer audio divestiture. Total revenue was $371.5M, up from $343.3M a year ago, with operating income rising to $83.6M from $38.2M. Net income from continuing operations was $53.7M versus $24.3M last year, while the company recorded a net loss from discontinued operations of $(154.1)M tied to the sale of Sound United.
Masimo closed the Sound United sale on September 23, 2025. On the balance sheet, cash and cash equivalents increased to $312.3M from $123.6M, and long‑term debt declined to $559.1M from $714.3M. Year‑to‑date, operating cash flow was $157.3M and investing cash flow was $283.8M, aided by discontinued operations. Financing cash flow was $(306.1)M, including repurchases of common stock of $177.0M. Shares outstanding were 53,713,949 as of September 27, 2025.